Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 594

1.

Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.

Ziakas PD, Kourbeti IS, Mylonakis E.

Clin Ther. 2014 Feb 1;36(2):292-306.e1. doi: 10.1016/j.clinthera.2013.11.010. Epub 2014 Jan 17.

PMID:
24439393
2.
3.

Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.

Xu SX, Shen JL, Tang XF, Feng B.

Transplant Proc. 2013 Jan-Feb;45(1):407-14. doi: 10.1016/j.transproceed.2012.07.149.

PMID:
23375330
4.

Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.

Sohn HS, Lee TJ, Kim J, Kim D.

Clin Ther. 2009 May;31(5):1105-15; discussion 1066-8. doi: 10.1016/j.clinthera.2009.05.011.

PMID:
19539111
5.

Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.

Park S, Kim K, Jang JH, Kim SJ, Kim WS, Chung DR, Kang CI, Peck KR, Jung CW.

J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7.

PMID:
27394404
6.

Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.

Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC.

Ann Intern Med. 2003 May 6;138(9):705-13.

PMID:
12729424
7.

Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.

Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1509-16. doi: 10.1016/j.bbmt.2012.03.014. Epub 2012 Mar 30.

8.

Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.

Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R.

Clin Ther. 2008 May;30(5):964-73. doi: 10.1016/j.clinthera.2008.04.020.

PMID:
18555943
9.

Role of new antifungal agents in prophylaxis of mycoses in high risk patients.

van Burik JA.

Curr Opin Infect Dis. 2005 Dec;18(6):479-83. Review.

PMID:
16258319
10.

Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.

Ping B, Zhu Y, Gao Y, Yue C, Wu B.

Ann Hematol. 2013 Jun;92(6):831-9. doi: 10.1007/s00277-013-1693-5. Epub 2013 Feb 28. Review.

PMID:
23455400
11.

Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.

Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S.

Cancer. 2002 Jun 15;94(12):3230-46.

12.

Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.

Chen Q, Lin MH, Chen ML, Liu ZY, Chai D, Wang R.

Chin Med J (Engl). 2012 Jan;125(2):345-51.

PMID:
22340571
13.

Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.

Vardakas KZ, Michalopoulos A, Falagas ME.

Br J Haematol. 2005 Oct;131(1):22-8. Erratum in: Br J Haematol. 2006 Mar;132(5):665.

PMID:
16173959
14.

[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].

Salavert-Lletí M, Zaragoza-Crespo R.

Rev Iberoam Micol. 2009 Mar 31;26(1):81-9. doi: 10.1016/S1130-1406(09)70015-4. Epub 2009 May 7. Review. Spanish.

15.

Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.

Pienaar ED, Young T, Holmes H.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD003940. doi: 10.1002/14651858.CD003940.pub3. Review.

PMID:
21069679
16.

Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.

Bow EJ, Vanness DJ, Slavin M, Cordonnier C, Cornely OA, Marks DI, Pagliuca A, Solano C, Cragin L, Shaul AJ, Sorensen S, Chambers R, Kantecki M, Weinstein D, Schlamm H.

BMC Infect Dis. 2015 Mar 17;15:128. doi: 10.1186/s12879-015-0855-6. Review.

17.

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.

Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK.

Cochrane Database Syst Rev. 2014 Feb 24;(2):CD004707. doi: 10.1002/14651858.CD004707.pub3. Review.

PMID:
24563222
18.

Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.

Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M.

J Clin Oncol. 2007 Dec 1;25(34):5471-89. Epub 2007 Oct 1. Review.

PMID:
17909198
19.

Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.

Pechlivanoglou P, Le HH, Daenen S, Snowden JA, Postma MJ.

J Antimicrob Chemother. 2014 Jan;69(1):1-11. doi: 10.1093/jac/dkt329. Epub 2013 Aug 23. Review.

PMID:
23975736
20.

A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.

Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L, Gorelik A, Dally N, Zuckerman T, Haddad N, Fineman R, Dann EJ.

Bone Marrow Transplant. 2006 Jul;38(2):127-34. Epub 2006 Jun 5.

PMID:
16751782

Supplemental Content

Support Center